NEW YORK, Oct. 27 (GenomeWeb News) - Genmab has reached a second milestone in its ongoing antibody development collaboration with Roche, having reached the proof of concept stage with a human antibody, the companies said today.
The size of the milestone was not disclosed.
The partnership was formed in May 2001, and calls for Genmab to create human antibodies against a variety of disease targets provided by Roche. Genmab stands to receive up to $100 million in milestones, as well as royalties on sales of products resulting from the deal. Genmab may also obtain the right to develop certain products based on disease targets identified by Roche.
The companies said that they now have moved two antibodies into the proof of concept stage of development.